Immuneering Corp Ordinary Shares Class A IMRX 深 沪
等待开盘 08-13 09:30:00 美东时间
3.25
+0.040
+1.25%
华盛通- 最 高3.25
- 今 开3.24
- 成交量 44.76万股
- 最 低 3.035
- 昨 收 3.21
- 总市值 1.17亿
- 52周最高 4.6892
- 市盈率 静 --
- 换手率 1.24%
- 52周最低 1.06
- 委 比 -91.25%
- 总股本 3598.57万
- 历史最高 33.99
- 量 比 1.86
- 振 幅 6.70%
- 历史最低 1.00
- 每 手 1
- 风险率 2.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immuneering rises on U.S. patent grant for atebimetinib
Shares of Immuneering (NASDAQ:IMRX) rose after the company said it has received a patent from the U.S. Patent and Trademark Office for its cancer drug candidate, atebimetinib. The stock is up 9%. Ateb...
07-10 01:21
Immuneering Granted U.S. Composition of Matter Patent For Atebimetinib
- Newly issued U.S. composition of matter patent expected to provide exclusivity into 2042, with subsequent opportunity for patent term extension -- First U.S. patent granted on a deep cyclic inhibitor: a once-daily pill
07-09 20:09
美股大行评级 | 潜在涨幅261.01%！瑞穗上调Immuneering目标价至10美元，维持"跑赢大市"评级
康托·菲茨杰拉德：维持Meta Platforms(META)"超配"评级，目标价从676美元升至807美元
06-19 09:23
Chardan Capital Maintains Buy on Immuneering, Maintains $13 Price Target
Chardan Capital analyst Geulah Livshits maintains Immuneering (NASDAQ:IMRX) with a Buy and maintains $13 price target.
06-18 19:02
Immuneering Announces Promising Phase 2a Trial Results
Immuneering ( ($IMRX) ) has issued an announcement. On June 17, 2025, Immuneeri...
06-17 18:28
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
Immuneering Corporation reported positive Phase 2a data for atebimetinib in combination with modified Gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. The treatment showed 94% overall survival (OS) and 72% progression-free survival (PFS) at 6 months, with a 39% overall response rate and 81% disease control rate. Atebimetinib demonstrated a favorable tolerability profile. The company plans a pivotal trial for 2026 and will host...
06-17 10:00
Immuneering shares are trading higher after the company announced it will provide updates from its Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients.
Immuneering shares are trading higher after the company announced it will provi...
06-16 20:39
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
<p>Immuneering Corporation announced it will host a conference call and live webcast on June 17, 2025, at 8:00 am ET, to update on its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients. The webcast will be available on the company's Investor Relations website. IMM-1-104 is an oral, once-daily MEK inhibitor targeting MAPK pathway-driven tumors like pancreatic cancer. For more information, visit www.immuneering.c...
06-16 12:00
美股大行评级 | 潜在涨幅6326.33%！Ascendiant Capital上调Plus Therapeutics目标价至20.5美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1137665801621229569.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Plus Therapeutics(PSTV)"买入"评级，目标价从20美元升至20.5美元</p> <p>• Ascendiant Capital：维持RenovoRx(RNXT
06-06 09:45
Needham Reiterates Buy on Immuneering, Maintains $9 Price Target
Needham analyst Ami Fadia reiterates Immuneering (NASDAQ:IMRX) with a Buy and maintains $9 price target.
06-05 19:15
